The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.
The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback